A double blind, randomised, placebo controlled, crossover ascending dose, safety and pharmacokinetics study of NMB46 in healthy volunteers.

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2018
This article has no abstract
Epistemonikos ID: b07500b7571e75dfae48c044621ebd81d9a66b22
First added on: Apr 11, 2025